When timely angioplasty is unavailable to older ST-segment elevation myocardial infarction (STEMI) patients, a modified pharmaco-invasive reperfusion strategy could be reasonable, according to the ...
NEW ORLEANS, LA—When timely primary PCI is not possible, a pharmacoinvasive strategy of half-dose tenecteplase may provide a safe and effective reperfusion alternative in older patients with STEMI, ...
When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...
A study concludes that a low-dose of the clot-busting drug—tenecteplase—may be beneficial for eligible stroke patients that do not need an intervention for the mechanical removal of a clot.
Tenecteplase for acute ischemic stroke provided similar safety and effectiveness outcomes as alteplase, a new study showed, suggesting the drug is a viable alternative treatment. This comparative ...
LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results